C

CASI Pharmaceuticals Inc
NASDAQ:CASI

Watchlist Manager
CASI Pharmaceuticals Inc
NASDAQ:CASI
Watchlist
Price: 5.75 USD 3.6%
Market Cap: 77.1m USD
Have any thoughts about
CASI Pharmaceuticals Inc?
Write Note

CASI Pharmaceuticals Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

CASI Pharmaceuticals Inc
Total Equity Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
C
CASI Pharmaceuticals Inc
NASDAQ:CASI
Total Equity
$24.2m
CAGR 3-Years
-33%
CAGR 5-Years
-26%
CAGR 10-Years
5%
Abbvie Inc
NYSE:ABBV
Total Equity
$6B
CAGR 3-Years
-24%
CAGR 5-Years
N/A
CAGR 10-Years
3%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$18.4B
CAGR 3-Years
-5%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$7.5B
CAGR 3-Years
-3%
CAGR 5-Years
-7%
CAGR 10-Years
-11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$15.6B
CAGR 3-Years
18%
CAGR 5-Years
24%
CAGR 10-Years
30%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$29.3B
CAGR 3-Years
19%
CAGR 5-Years
23%
CAGR 10-Years
28%

See Also

What is CASI Pharmaceuticals Inc's Total Equity?
Total Equity
24.2m USD

Based on the financial report for Dec 31, 2023, CASI Pharmaceuticals Inc's Total Equity amounts to 24.2m USD.

What is CASI Pharmaceuticals Inc's Total Equity growth rate?
Total Equity CAGR 10Y
5%

Over the last year, the Total Equity growth was -46%. The average annual Total Equity growth rates for CASI Pharmaceuticals Inc have been -33% over the past three years , -26% over the past five years , and 5% over the past ten years .

Back to Top